Sun Pharmaceutical Industries Posts Double-Digit Growth in Revenue and Net Profit for March Quarter
मुख्य बातें
- •Sun Pharmaceutical Industries reports double-digit growth in revenue and net profit for the March quarter.
- •The company's EBITDA margin is under pressure due to higher investments and lower milestone income from products.
- •The company expects revenue growth to moderate in FY27, with growth slowing down to high single-digit.
- •The pipeline across dermatology, oncology, and metabolic therapies, along with new launches and the proposed Organon acquisition, will be key growth drivers.
- •The company's R&D spends are expected to remain elevated at about 6-7% of sales for FY27, which may put pressure on profitability in the near term.
Sun Pharmaceutical Industries has reported a double-digit growth in revenue and net profit for the March quarter, driven by strong performance in the domestic formulation segment and new launches. However, the company's operating margin before depreciation and amortisation (EBITDA margin) was under pressure due to higher investments and lower milestone income from products. The EBITDA margin contracted 160 basis points year-on-year to an eight-quarter low of 27.1% in the March quarter.
